Skip to main content
. 2018 Apr 17;109(5):1552–1561. doi: 10.1111/cas.13550

Figure 2.

Figure 2

Progression‐free survival (A) and overall survival (B) of patients with relapsed or refractory multiple myeloma who were randomized to bortezomib plus dexamethasone (BD) or thalidomide plus dexamethasone (TD) treatment arms from the time of study enrollment